Quinolinone PDE2 inhibitors
US8680116B2 · kind B2 · utility
9Cited by
3References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 19, 2010 |
| Grant date | Mar 25, 2014 |
| Priority date | — |
| Expiry date | Dec 25, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D409/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to quinolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.